As per DelveInsight’s EPI Epidemiological analysis, a total of 80,641 Exocrine Pancreatic Insufficiency cases were reported due to Acute Pancreatitis, and 237,255 cases due to Chronic Pancreatitis. At the same time, Cystic Fibrosis and Unresectable Pancreatic Cancer caused 62,204 and 59,036 EPI cases, respectively, in 2017 in the 7MM.
The market size of Exocrine Pancreatic Insufficiency in the seven major markets was estimated to be approximately USD 1,695.26 Million in 2017.
To address the unmet needs in the Exocrine Pancreatic Insufficiency market, pharma companies such as CHIESI FARMACEUTICI S.P.A., AzurRx BioPharma, Inc., and many others are investing in developing novel therapeutic approaches in their Exocrine Pancreatic Insufficiency pipeline to change the treatment landscape of EPI entirely.
For more details visit:
https://www.delveinsight.com/blog/exocrine-pancreatic-insufficiency-market/